BristolMyers Squibb to Acquire Mirati in Up to 5.8B Deal
Oct 8 Reuters BristolMyers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to 5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade. Bristol will pick up Mirati39;s portfolio drugs that target the genetic drivers of specific cancers including […]